Title	Objective response rate after 3 cycles of treatment, safety throughout the study period
Number of patients screened	32
Number of patients enrolled	13
Number of patients evaluable for toxicity	13
Number of patients evaluated for efficacy	13
Evaluation method	RECIST 1.1
Response assessment, CR	5 (38.5%)
Response assessment, PR	5 (38.5%)
Response assessment, SD	3 (23.1%)
Response assessment, PD	0 (0%)
Median duration assessment, PFS	9.3 months (95% CI: 5.8-30.4 months)
Median duration assessment, OS	The median OS and its 95% CI could not be estimated because the estimated OS at the last time point of 49.3 months was >50%.
Response duration	12.8 months (95% CI: 1.4 to ≥28.5 months)
Duration of treatment	The median number of treatment cycles for combination therapy was 7 (range, 3-21)